206 related articles for article (PubMed ID: 30929537)
1. Development and validation of a versatile HPLC-DAD method for simultaneous determination of the antiviral drugs daclatasvir, ledipasvir, sofosbuvir and ribavirin in presence of seven potential impurities. Application to assay of dosage forms and dissolution studies.
Baker MM; Hammad SF; Belal TS
Drug Dev Ind Pharm; 2019 Jul; 45(7):1111-1119. PubMed ID: 30929537
[TBL] [Abstract][Full Text] [Related]
2. Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms.
Ezzeldin E; Abo-Talib NF; Tammam MH; Asiri YA; Amr AEE; Almehizia AA
Molecules; 2020 Oct; 25(20):. PubMed ID: 33050433
[TBL] [Abstract][Full Text] [Related]
3. Optimization of a sensitive and robust strategy for micellar electrokinetic chromatographic analysis of sofosbuvir in combination with its co-formulated hepatitis C antiviral drugs.
Rageh AH; Abdel-Aal FAM; Pyell U
J Chromatogr A; 2020 Apr; 1616():460795. PubMed ID: 31918849
[TBL] [Abstract][Full Text] [Related]
4. Investigation of anti-Hepatitis C virus, sofosbuvir and daclatasvir, in pure form, human plasma and human urine using micellar monolithic HPLC-UV method and application to pharmacokinetic study.
Zidan DW; Hassan WS; Elmasry MS; Shalaby AA
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jun; 1086():73-81. PubMed ID: 29660665
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of six sequential spectrophotometric methods for quantification and separation of ribavirin, sofosbuvir and daclatasvir: An application on Laboratory prepared mixture, pharmaceutical preparations, spiked human urine, spiked human plasma, and dissolution test.
Hassan WS; Elmasry MS; Elsayed HM; Zidan DW
Spectrochim Acta A Mol Biomol Spectrosc; 2018 Sep; 202():159-173. PubMed ID: 29783148
[TBL] [Abstract][Full Text] [Related]
6. Chemometrically Assisted Development of Ultra-High-Performance Liquid Chromatography Method for the Simultaneous Quantification of Sofosbuvir, Daclatasvir and Ledipasvir in Pharmaceutical Dosage Forms.
Labidi A; El Atrache LL
J Chromatogr Sci; 2020 Jan; 57(10):910-919. PubMed ID: 31644804
[TBL] [Abstract][Full Text] [Related]
7. Validated RP-HPLC Method for Simultaneous Determination of Ribavirin, Sofosbuvir and Daclatasvir in Human Plasma: A Treatment Protocol Administered to HCV Patients in Egypt.
Youssef AA; Magdy N; Hussein LA; El-Kosasy AM
J Chromatogr Sci; 2019 Aug; 57(7):636-643. PubMed ID: 31063182
[TBL] [Abstract][Full Text] [Related]
8. Validated spectrophotometric and chromatographic methods for analysis of the recently approved hepatitis C antiviral combination ledipasvir and sofosbuvir.
Baker MM; El-Kafrawy DS; Mahrous MS; Belal TS
Ann Pharm Fr; 2018 Jan; 76(1):16-31. PubMed ID: 28842163
[TBL] [Abstract][Full Text] [Related]
9. Efficient HPTLC-dual wavelength spectrodensitometric method for simultaneous determination of sofosbuvir and daclatasvir: Biological and pharmaceutical analysis.
Abo-Zeid MN; El-Gizawy SM; Atia NN; El-Shaboury SR
J Pharm Biomed Anal; 2018 Jul; 156():358-365. PubMed ID: 29753282
[TBL] [Abstract][Full Text] [Related]
10. Development a validated highly sensitive LC-MS/MS method for simultaneous quantification of Ledipasvir, sofosbuvir and its major metabolite GS-331007 in human plasma: Application to a human pharmacokinetic study.
Abdallah OM; Abdel-Megied AM; Gouda AS
J Pharm Biomed Anal; 2017 Sep; 143():305-310. PubMed ID: 28645021
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of LC-MS/MS method for simultaneous determination of sofosbuvir and daclatasvir in human Plasma: Application to pharmacokinetic study.
Abdallah OM; Abdel-Megied AM; Gouda AS
Biomed Chromatogr; 2018 Jun; 32(6):e4186. PubMed ID: 29314090
[TBL] [Abstract][Full Text] [Related]
12. New, simple and sensitive HPTLC method for simultaneous determination of anti-hepatitis C sofosbuvir and ledipasvir in rabbit plasma.
El-Gizawy SM; El-Shaboury SR; Atia NN; Abo-Zeid MN
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Aug; 1092():432-439. PubMed ID: 29945107
[TBL] [Abstract][Full Text] [Related]
13. UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients.
Notari S; Tempestilli M; Fabbri G; Libertone R; Antinori A; Ammassari A; Agrati C
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1073():183-190. PubMed ID: 29276983
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits.
Atia NN; El-Shaboury SR; El-Gizawy SM; Abo-Zeid MN
J Pharm Biomed Anal; 2018 Sep; 158():88-93. PubMed ID: 29864695
[TBL] [Abstract][Full Text] [Related]
15. Development of a highly sensitive high-performance thin-layer chromatography method for the screening and simultaneous determination of sofosbuvir, daclatasvir, and ledipasvir in their pure forms and their different pharmaceutical formulations.
Saraya RE; Elhenawee M; Saleh H
J Sep Sci; 2018 Sep; 41(18):3553-3560. PubMed ID: 30048040
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a stability-Indicating RP-HPLC method for simultaneous estimation of sofosbuvir and velpatasvir in fixed dose combination tablets and plasma.
Mehmood Y; Khan IU; Shahzad Y; Khalid SH; Irfan M; Asghar S; Yousaf AM; Hussain T; Khalid I
Pak J Pharm Sci; 2019 Jul; 32(4(Supplementary)):1835-1842. PubMed ID: 31680080
[TBL] [Abstract][Full Text] [Related]
17. Rapid and sensitive UHPLC-DAD method for simultaneous determination of sofosbuvir and ledipasvir in human serum.
Majnooni MB; Miraghaee SS; Keshavarzi S; Mohammadi B; Sajadimajd S; Hatami R; Bahrami G
J Pharm Biomed Anal; 2021 Feb; 195():113860. PubMed ID: 33387837
[TBL] [Abstract][Full Text] [Related]
18. Earth-friendly spectrophotometric methods for simultaneous determination of ledipasvir and sofosbuvir: Application to average content and uniformity of dosage unit testing.
El-Shorbagy HI; Elsebaei F; Hammad SF; Elbrashy AM
Spectrochim Acta A Mol Biomol Spectrosc; 2018 Dec; 205():398-409. PubMed ID: 30044997
[TBL] [Abstract][Full Text] [Related]
19. Validated specific HPLC-DAD method for simultaneous estimation of paracetamol and chlorzoxazone in the presence of five of their degradation products and toxic impurities.
El-Yazbi AF; Guirguis KM; Bedair MM; Belal TS
Drug Dev Ind Pharm; 2020 Nov; 46(11):1853-1861. PubMed ID: 32894703
[TBL] [Abstract][Full Text] [Related]
20. A Stability-Indicating UPLC Method for the Determination of Potential Impurities and Its Mass by a New QDa Mass Detector in Daclatasvir Drug Used to Treat Hepatitis C Infection.
Jagadabi V; Nagendra Kumar PV; Mahesh K; Pamidi S; Ramaprasad LA; Nagaraju D
J Chromatogr Sci; 2019 Jan; 57(1):44-53. PubMed ID: 30169761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
